Mainstay Medical announces 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization

Dublin, Ireland: 15 February 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain, announces today that it has raised gross proceeds of €30.1 million through the issue of 2,151,332 new ordinary shares (New Shares) to new and existing shareholders.

More info on Mainstay Medical's website.

Next > Confo Therapeutics is awarded a 1 million grant to increase its screening capabilities

Previous > Mainstay Medical publishes 2017 full year results